Question Description
Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? for UPSC 2024 is part of UPSC preparation. The Question and answers have been prepared according to the UPSC exam syllabus. Information about Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? covers all topics & solutions for UPSC 2024 Exam. Find important definitions, questions, meanings, examples, exercises and tests below for Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer?.

Solutions for Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? in English & in Hindi are available as part of our courses for UPSC. Download more important topics, notes, lectures and mock test series for UPSC Exam by signing up for free.

Here you can find the meaning of Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? defined & explained in the simplest way possible. Besides giving the explanation of Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer?, a detailed solution for Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? has been provided alongside types of Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? theory, EduRev gives you an ample number of questions to practice Growth through acquisitions and alliances has become a critical part of creating value for pharma and biotech manufacturers and their shareholders. However, companies and their investors may risk value destruction if they acquire rights to a drug that suddenly poses unanticipated safety risks for patients. Similarly, safety related compliance violations committed by an acquired company could significantly impair the ultimate value of the transaction and the reputation of the acquirer. The pace of deal making between pharma and biotech companies continued to accelerate in 2006, increasing 17% to about $ 18 billion. Pharma companies were typically the buyers, and the premiums they paid increased substantially as competition intensified, to secure access to novel drugs and biologics. The stakes increase everyday as competition pushes up prices and drives deal making to earlier development stages with greater uncertainty and less time to complete thorough due diligence—Q. Which of the following inference(s) is/are definitely true?a)Acquisitions of biotech companies was preferred among pharmaceutical companies in the recent past.b)Biotech companies are not capable to acquire pharmaceutical companies.c)Safety related issues are prime concerns for the pharmaceutical companies while negotiating acquisitions of biotech companies.d)Stiff competitions among the prospective buyers have resulted into erosion of value of the biotech companies.Correct answer is option 'A'. Can you explain this answer? tests, examples and also practice UPSC tests.